Changchun BCHT Biotechnology Co.

BCHT was established in March 2004 by the investment of Changchun High-technology Industry Development Property (Group). The company is a high-tech enterprise engaged in research, development, production and marketing of biologics and drugs. BCHT now owns four manufacturing sites which cover 235,000 square meters in total and two R&D centers for vaccine and drug with the most equipped laboratories and pilot plants in the areas over 5000 square meters. For the last few years, the company’s R&D investment exceeds over 120 million RMB. Represented by development of the new AIDS preventive vaccine, the company has carried out more than 50 R&D projects in innovative biologics and peptide drugs, resulted in 2 certificates for production and 12 approvals for clinical trial from SFDA. At present, there are 13 key vaccine projects. The company submitted 33 patent applications in which 11 patents have been granted. BCHT has been awarded as High-tech Enterprise, AAA Credit Enterprise, Quality Creditable Enterprise and assigned as Engineering Research Center for Modern Vaccines, Innovative Center for Science and Technology of Vaccine, Engineering Research Center for Vaccines at Changchun State Bio-Industry Base by Jilin province. BCHT has co-established National Engineering Laboratory for AIDS Vaccine with Jilin University. In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extension of the vaccine shelf-life up to 36 months which is the longest one in the world. These improvements enhanced the vaccine safety and quality, and established BCHT the leading position in varicella vaccine. At present, the company has 13 key vaccine projects including Acellular DTP vaccine, live attenuated influenza vaccine (LAIV), HPV vaccine which will be launched to the market in the next few years. Jilin Maifeng Biopharmaceutical Co., Ltd., a subsidiary of BCHT, is devoted to mostly R&D in high density cell culture technique and its application for large scale production. Jilin Maifeng is the first company to develop and apply the self-developed microcarrier bioreactor technology to produce rabies vaccine for human use. BCHT is in a fast-growing stage to approach the advanced international level in quality, marketing, management and human resource, aiming at becoming a first-class biopharmaceutical enterprise in the world.